StockWatch
·

Dishman Carbogen Amcis Ltd

BSE: 540701

P/L Snapshot

Q1 FY27 · standalone

vs Q3 FY26·vs Q1 FY26
Revenue
75.97
+62.4%-24.2%
Expenditure
105.98
+29.5%+10.2%
Net Profit
-23.91
-3.4%-995.5%
OPM %
-23.67%
-14.85pp-29.13pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
-41.544.0049.5395.07140.61Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q1 FY27
Price Chart
Reports

Dishman Carbogen swings to Rs57.9 Cr consolidated loss as margins crash to 8.9% YoY

cdmo · pharma api · margin compression

ResultsQ1 FY2714 Aug 20263 minPharma & Healthcare
Latest
Board Meeting14 Aug, 8:01 pm

Dishman Carbogen swings to Rs57.9 Cr consolidated loss as margins crash to 8.9% YoY

Dishman Carbogen Amcis (consolidated, the primary basis) posted a net loss of Rs57.88 Cr in Q1 FY27, reversing a Rs23.41 Cr profit in Q1 FY26 and a Rs21.74 Cr profit in Q4 FY26 - a turnaround to loss on both a YoY and QoQ basis, with EPS at -Rs3.69 versus +Rs1.49 a year ago. Revenue from operations fell 4.3% YoY to Rs677.64 Cr and 20.4% QoQ from Rs851.40 Cr (Q4 is seasonally the group's strongest quarter). Operating margin (EBITDA/revenue, company-reported) collapsed to 8.87% from 19.87% YoY and 19.14% QoQ, and net margin swung to -8.54% from +3.31% YoY - a sharp compression on both lines. The squeeze sits mainly on employee costs, not the one-off item: employee benefits expense rose to 57.4% of revenue (Rs389.10 Cr) from 49.7% YoY (Rs351.90 Cr) even as revenue declined, the single largest driver of the margin collapse. Net material cost (cost of materials consumed adjusted for inventory changes) also rose to roughly 16.9% of revenue from 13.9% YoY. A Rs1.69 Cr exceptional charge for abandoned QIP transaction costs hit PBT on both standalone and consolidated statements, but pre-exceptional operating profit was already negative Rs49.53 Cr consolidated - adjusting both years for their respective exceptional items still shows a swing from an adjusted profit of roughly Rs26 Cr a year ago to an adjusted loss of roughly Rs56 Cr now, so the one-off is not what drove this into the red. Standalone (the India entity) was weaker still, with a net loss of Rs23.91 Cr versus a Rs2.67 Cr profit YoY on just Rs57.08 Cr of revenue and operating margin of -20.71%, underscoring that India operations remain a small, currently loss-making sliver of a group whose scale sits in the European/Swiss subsidiaries. No specific street consensus for this quarter surfaced in available coverage; broker commentary instead frames a broader FY27 earnings-recovery thesis built on easing input costs and a richer revenue mix, a thesis this print does not support in its first quarter. Against management's own prior guidance - a Q3 FY26 concall target of restoring consolidated EBITDA margin to 25-26% within two years, alongside a French-facility breakeven goal for FY27 - this quarter's 8.87% margin is a clear miss and a step in the wrong direction from that trajectory; the FY26 full-year margin guidance of 19.5-20% itself was roughly met in Q4 FY26 (19.14%) but that guidance window has now closed. Management's own framing in the filing (note 9) attributes the exceptional charge to abandoning a planned QIP equity raise 'due to adverse market conditions and an altered fundraising plan' - consistent with the company instead raising debt this quarter (Rs18 Cr of NCDs placed on June 9) and immediately after quarter-end (board approval for a further Rs75 Cr NCD issuance on August 12); consolidated debt-equity rose to 0.48x from 0.35x YoY, evidence of the pivot from equity to debt funding. This sets up Q2 FY27 as the quarter to watch for whether the employee-cost ratio normalizes and whether management addresses the gap between this print and its 25-26% margin ambition, given the prior concall's confident, 'very optimistic' long-term tone now stands in direct tension with a quarter that swung the group into loss.

14 Aug 2026, 08:01 pm

Corporate Events

Board MeetingDCAL
2026
30Sep

Board Meeting

The Annual General Meeting ("AGM") of members of the Company…

BSE Filing
Board MeetingDCAL
2026
12Aug

Board Meeting

The Board of Directors will meet to consider and approve the…

BSE Filing
Board MeetingDCAL
2026
19Jun

Board Meeting

The Extra-Ordinary General Meeting (EGM) is scheduled to be …

BSE Filing
Board MeetingDCAL
2026
18Mar

Board Meeting

To consider and approve the proposal of fund raising by way …

BSE Filing
Board MeetingDCAL
2024
13Nov

Board Meeting

Consider, take on record and approve the Un-Audited Financia…

BSE Filing
Board MeetingDCAL
2024
13Aug

Board Meeting

Consider, take on record and approve the Un-Audited Financia…

BSE Filing
Board MeetingDCAL
2024
30May

Board Meeting

consider and approve the Audited Financial Results for the q…

BSE Filing
Board MeetingDCAL
2024
14Feb

Board Meeting

Consider and approve Un-Audited Financial Results for the th…

BSE Filing
Board MeetingDCAL
2023
8Nov

Board Meeting

Consider and approve Un-Audited Financial Results of the Com…

BSE Filing
Board MeetingDCAL
2023
9Aug

Board Meeting

consider and approve the Un-Audited Financial Results for Q1…

BSE Filing